HCV; the Rising Concerns and Growing Hopes 2007;46(2):297-306. 10. Gressner OA, Weiskirchen R, Gressner AM. Biomarkers of hepatic fibrosis, fibrogenesis and genetic pre-disposition pending be- tween fiction and reality. J Cell Mol Med. 2007;11(5):1031-51. 11. Jeffers LJ, Cassidy W, Howell CD, Hu S, Reddy KR. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology. 2004;39(6):1702-8. 12. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr., et al. Peginterferon alfa-2a plus ribavirin for chronic hepa- titis C virus infection. N Engl J Med. 2002;347(13):975-82. 13. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez- Garcia J, Lazzarin A, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351(5):438-50. 14. Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med. 2004;350(22):2265-71. 15. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shi M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358(9286):958-65. 16. Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benze- kri A, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected pa- tients: a randomized controlled trial. JAMA. 2004;292(23):2839- 48. 17. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1207-17. 18. Lindenbach BD, Rice CM. Unravelling hepatitis C virus replica- tion from genome to function. Nature. 2005;436(7053):933-8. 19. Swain MG, Lai MY, Shiffman ML, Cooksley WG, Zeuzem S, Diet- erich DT, et al. A sustained virologic response is durable in pa- tients with chronic hepatitis C treated with peginterferon alfa-2a Alavian SM et al. and ribavirin. Gastroenterology. 2010;139(5):1593-601. 20. Foster G, Mathurin P. Hepatitis C virus therapy to date. Antivir Ther. 2008;13 (Suppl 1):3-8. 21. Friedman RM, Contente S. Treatment of hepatitis C infec- tions with interferon: a historical perspective. Hepat Res Treat.2010:323926. 22. McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology. 2002;123(4):1061-9. 23. Jabari H, Zamani F, Hatami K, Sheikholeslami A, Fakharzadeh E, Shahzamani K, et al. Pegaferon in hepatitis C: Results of a Multi- center Study. MEJDD. 2011;3(2):110-4. 24. Jabbari H, Bayatian A, Sharifi AH, Zaer-Rezaee H, Fakharzadeh E, Asadi R, et al. Safety and efficacy of locally manufactured pegylated interferon in hepatitis C patients. Arch Iran Med. 2010;13(4):306-12. 25. Lo Re V, 3rd, Teal V, Localio AR, Amorosa VK, Kaplan DE, Gross R. Relationship between adherence to hepatitis C virus ther- apy and virologic outcomes: a cohort study. Ann Intern Med. 2011;155(6):353-60. 26. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, Mc- Cone J, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361(6):580- 93. 27. EASL Clinical Practice Guidelines: management of hepatitis C vi- rus infection. J Hepatol. 2011;55(2):245-64. 28. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An up- date on treatment of genotype 1 chronic hepatitis C virus infec- tion: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54(4):1433-44. 29. Manns M, Lindsay KL, Gordon SC, Pockros PJ, Haeussinger D, Hadziyannis S, et al. Sustained virological response after pegin- terferon alpha 2b and ribavirin predicts long-term clearance of HCV at 5 year follow up. J Hepatol. 2008;48:S300. Hepat Mon. 2012 429